For patients with HER2+ BC disease, the novel HER2DX is a prognostic and predictive GEA encompassing 27 gene expression levels including ErbB2 mRNA, which, in combination with clinical and tumor features, identifies four gene signature profiles (immune, proliferation, luminal differentiation, and HER2 amplicon) [103]. This evidence concerns the gene ERBB2 and breast cancer.